OMER - オメロス （Omeros Corporation） オメロスOMERのチャート
OMERの企業情報
| symbol | OMER |
|---|---|
| 会社名 | Omeros Corp （オメロス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 オメロス(Omeros Corporation)はバイオ医薬品会社である。同社は大規模市場、炎症、凝固障害及び中枢神経系の障害を標的とする孤児の適応症のための小分子及びタンパク質治療薬の発見、開発、商業化に従事する。白内障手術と眼内レンズ（IOL）の交換時に市販されている医薬品Omidria（フェニレフリンとケトロラク注射）が使用される。Omidriaは、眼科的、関節鏡的、泌尿器科学的及び他の外科的処置を受けている患者のために設計されたPharmacoSurgeryプラットフォームに由来する。PharmacoSurgeryプラットフォームは、米国食品医薬品局（FDA）が承認した治療薬の低用量の組み合わせに基づいて、手術中に炎症と先天性外傷による他の問題を抑制するための手術期間中、 手術中及び手術後の両方で臨床的補助を提供する。 オメロスは米国のバイオ医薬品企業。炎症、凝固障害、中枢神経系障害の治療薬の開発、商品化に従事。眼科学向けOMS302、関節鏡処置OMS103HP、泌尿器科向けOMS201、認知障害OMS824、虐待依存症向けPPARg Programなどの臨床プログラムを手掛けるほか、運動障害治療向けOMS527などの前臨床プログラムを手掛ける。 Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under priority review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in a Phase 1 clinical trial, and the company's PDE7 inhibitor program OMS527, targeting addiction and movement disorders, has successfully completed a Phase 1 trial. Omeros' pipeline holds a diverse group of preclinical programs including a proprietary-asset-enabled antibody-generating technology and a proprietary GPCR platform through which it controls 54 GPCR drug targets and their corresponding compounds. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing GPR174-targeting antibodies and small-molecule inhibitors. |
| 本社所在地 | 201 Elliott Avenue West Seattle WA 98119 USA |
| 代表者氏名 | Gregory A. Demopulos グレゴリーA.デモプス |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 206-676-5000 |
| 設立年月日 | 34486 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2009年 |
| 従業員数 | 173人 |
| url | www.omeros.com |
| nasdaq_url | https://www.nasdaq.com/symbol/omer |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -76.79100 |
| 終値（lastsale） | 14.75 |
| 時価総額（marketcap） | 716257286 |
| 時価総額 | 時価総額（百万ドル） 770.15870 |
| 売上高 | 売上高（百万ドル） 38.66000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 812.11270 |
| 当期純利益 | 当期純利益（百万ドル） -87.78300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Omeros Corporation revenues decreased 89% to $3.2M. Net loss increased from $29.4M to $63.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 55% to $35.2M (expense) Interest expense increase of 21% to $6.5M (expense). |
OMERのテクニカル分析
OMERのニュース
Omeros stock reports positive data for rare blood disorder candidate 2023/04/25 14:15:15 Seeking Alpha
Omeros Corporation (OMER) announced Tuesday Phase 1 data for OMS906, its candidate for rare hematological disease paroxysmal nocturnal hemoglobinuria. Read more here.
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria 2023/04/25 13:25:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced positive results from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company’s lead MASP-3 inhibitor, in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening hemolytic blood disorder. Statistically significant and clinically meaningful improvements were observed in all measured markers of hemolysis, including hemoglobin (Hgb
Omeros awarded $6.69M grant from NIH for cocaine use disorder treatment 2023/04/10 14:13:43 Seeking Alpha
–Omeros (OMER) said it had been granted $6.69M from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop its lead proprietary PDE7…
Omeros Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program 2023/04/10 12:47:02 Investing.com
https://www.investing.com/news/assorted/omeros-awarded-669-million-grant-from-the-national-institute-on-drug-abuse-for-its-oms527-addiction-program-432SI-3051654
Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program 2023/04/10 12:45:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD). The grant is expected to provide $6.69 million over three years and is intended to support both preclinical cocaine interaction stud
Omeros Corporation (NASDAQ:OMER) stock: You might be surprised 2022/09/15 16:00:00 US Post News
Currently, Omeros Corporation’s (OMER) stock is trading at $4.05, marking a fall of -24.86% from last night’s close. At this price, the stock is -75.15% below its 52-week high of $16.30 and 118.33% above its 52-week low of $1.86. Based on the past 30-day period, the stock price is -41.67% below the high and +14.75% […]
Omeros (NASDAQ:OMER) Tanks on COVID-19 Therapy Data 2022/09/15 14:39:04 TipRanks
Shares of biopharmaceutical company Omeros Corp. (NASDAQ:OMER) are tanking today after data from its I-SPY COVID-19 trial arm for narsoplimab failed to impress investors. The drug indicated lower mortality risk on its addition to the treatment of critically ill COVID-19 patients. All the patients received standard of care which included dexamethasone and remdesivir. The drug though was not seen to shorten the time to recovery for patients. The data monitoring committee terminated the arm that included narsoplimab before reaching 125 patients and importantly, “Neither the trial’s futility nor graduation criteria had been met in the analysis of the population at the time of termination of the arm.
HeartBeam, NeuroBo top healthcare gainers; Shuttle, Omeros lead losers'' pack 2022/09/15 14:03:46 Seeking Alpha
HeartBeam BEAT +55%. NeuroBo Pharmaceuticals (NRBO) +52%. Shuttle Pharmaceuticals (SHPH) -23%. Omeros OMER -19%.
OMER stock falls after reporting trial data for COVID-19 therapy (NASDAQ:OMER) 2022/09/15 13:44:11 Seeking Alpha
The shares of commercial-stage biopharma, Omeros Corporation (OMER) fell ~11% in the morning hours Thursday after the company reported data from a clinical trial…
We Just Learned Something New About Omeros Corporation (NASDAQ: OMER) This Week With Its -34.92% Loss 2022/08/27 20:00:00 Marketing Sentinel
During the last session, Omeros Corporation (NASDAQ:OMER)’s traded shares were 0.53 million, with the beta value of the company hitting 1.16. At the end of the trading day, the stock’s price was $3.82, reflecting an intraday loss of -2.80% or -$0.11. The 52-week high for the OMER share is $16.57, that puts it down -333.77 … We Just Learned Something New About Omeros Corporation (NASDAQ: OMER) This Week With Its -34.92% Loss Read More »
Omeros stock rises 7% after beating Q1 earnings estimate 2022/05/11 16:27:02 Seeking Alpha
Omeros <> stock rose after the company posted better than-expected Q1 earnings, helped by royalties from ophthalmic product Omidria. Net loss for the quarter was $33M or $0.53…
52 Stocks Moving In Wednesday''s Mid-Day Session 2022/05/11 16:25:49 Benzinga
Gainers Trecora Resources (NYSE: TREC ) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of Balmoral Funds at $9.81 per share in cash or an enterprise value of $247 million. Exicure, Inc. (NASDAQ: XCUR ) rose 22.3% to $0.13 after the company reported a $5 million raise in private placement transaction priced at market premium. Purple Innovation, Inc. (NASDAQ: PRPL ) shares jumped 20.7% to $3.7664 after the company reported better-than-expected Q1 EPS and sales results. Endeavour Silver Corp. (NYSE: EXK ) surged 20% to $3.7291 following upbeat quarterly results. Ferroglobe PLC (NASDAQ: GSM ) gained 18.4% to $7.53 after the company reported better-than-expected Q1 EPS results. Celsius Holdings, Inc. (NASDAQ: CELH ) surged 16.4% to $48.10 after the company reported better-than-expected Q1 sales results. H&R Block, Inc. (NYSE: HRB ) gained 16% to $27.55 as the company posted upbeat Q3 results and raised FY22 sales guidance. Callaway Golf Company (NYSE: ELY ) jumped 15.9% to $20.81 after the company reported better-than-expected Q1 EPS and sales results and issued FY22 revenue guidance above analyst estimates.
Omeros Corporation (OMER) CEO Greg Demopulos on Q1 2022 Results - Earnings Call Transcript 2022/05/11 02:26:03 Seeking Alpha
Omeros Corporation (NASDAQ:NASDAQ:OMER) Q1 2022 Earnings Conference Call May 10, 2022 04:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman &…
Omeros GAAP EPS of -$0.53 beats by $0.08 2022/05/10 20:07:20 Seeking Alpha
Omeros press release (OMER): Q1 GAAP EPS of -$0.53 beats by $0.08.Omeros earned royalties of $13.8M based on Rayner’s net sales of $27.7M, all of which were in the U.S., a $6.6M…
Omeros Corporation Reports First Quarter 2022 Financial Results 2022/05/10 20:02:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2022, which include: On December